Wilson William, Gurvitch Ronen, Ajani Andrew E
Department of Cardiology, Royal Melbourne Hospital, Melbourne, Victoria 3050, Australia.
Cardiovasc Ther. 2009 Fall;27(3):194-8. doi: 10.1111/j.1755-5922.2009.00086.x.
The antiplatelet drug prasugrel is one of the new generations of thienopyridines, drugs that inhibit the platelet P2Y(12) receptor. It is becoming clear that there is variability in individual responses to antiplatelet agents such as clopidogrel, which may limit their efficacy and widespread utility. A number of controversies remain, such as varied definitions of "nonresponders" to antiplatelet therapy, the optimal means of assessing platelet function, and the potential capacity of in vivo platelet function studies to predict future clinical events. Prasugrel provides more rapid and consistent platelet inhibition than does clopidogrel, yet its clinical utility is under scrutiny. We aim to review the available data evaluating the efficacy and safety of this novel antiplatelet agent.
抗血小板药物普拉格雷是新一代噻吩并吡啶类药物之一，这类药物可抑制血小板P2Y(12)受体。越来越明显的是，个体对氯吡格雷等抗血小板药物的反应存在差异，这可能会限制其疗效和广泛应用。仍存在一些争议，例如抗血小板治疗“无反应者”的不同定义、评估血小板功能的最佳方法以及体内血小板功能研究预测未来临床事件的潜在能力。普拉格雷比氯吡格雷能更快速、更持续地抑制血小板，但它的临床效用仍在接受审查。我们旨在综述评估这种新型抗血小板药物疗效和安全性的现有数据。
